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Abstract
Objectives To describe the development of acronym use across five
major medical specialties and to evaluate the technical and aesthetic
quality of the acronyms.
Design Acronyms obtained through a literature search of Pubmed.gov
followed by a standardised assessment of acronym quality (BEAUTY
and CHEATING criteria).
Participants Randomised controlled trials within psychiatry,
rheumatology, pulmonary medicine, endocrinology, and cardiology
published between 2000 and 2012.
Main outcome measures Prevalence proportion of acronyms and
composite quality score for acronyms over time.
Results 14 965 publications were identified, of which 18.3% (n=2737)
contained an acronym in the title. Acronym use was more common
among cardiological studies than among the other four medical
specialties (40% v 8-15% in 2012, P<0.001). Except for within cardiology,
the prevalence of acronyms increased over time, with the average
prevalence proportion among the remaining four specialties increasing
from 4.0% to 12.4% from 2000 to 2012 (P<0.001). Themedian combined
acronym quality score decreased significantly over the study period
(P<0.001), from a median 9.25 in 2000 to 5.50 in 2012.
Conclusion From 2000 to 2012 the prevalence of acronyms in trial
reports increased, coinciding with a substantial decrease in the technical
and aesthetic quality of the acronyms. Strict enforcement of current
guidelines on acronym construction by journal editors is necessary to
ensure the proper use of acronyms in the future.
Introduction
Acronyms—abbreviations formed from the initial components
of a phrase or word1—improve the perception of complex,
written information.2 3 Within the health sciences, researchers’
use of acronyms holds a long tradition, with the likely intention
of branding their work into the minds of fellow researchers,
clinicians, editors, or lay people.4
The use of acronyms in health sciences has been subject to
intense debate.5 Authors have advocated against such use as
they claim it has turned into MMMMM—a major malady of
modernmedical miscommunication6—and asserted that positive
sounding acronyms are misused in clinical trials with negative
outcomes.7 8 It has been suggested that editors should insist on
eliminating the use of positive sounding acronyms9 or even
bring a HALT (help acronyms leave (medical) trials) to the use
of acronyms altogether.10
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This heated controversy seems to be based on opinion rather
than founded on rigorous scientific research. Few quantitative
studies of this important topic exist, and to our knowledge
studies on the technical and aesthetic quality of acronyms are
virtually absent. We describe the extent and quality of acronym
use within different medical specialties.
Methods
We included five major medical specialties in the analysis:
cardiology, endocrinology, rheumatology, pulmonarymedicine,
and psychiatry. For each specialty we selected a disease that
was central to the discipline and identified the most appropriate
MeSH term for that disease. Using these MeSH terms, we
searched PubMed for studies containing acronyms in their title
that did not refer to a method (for example, randomised
controlled trial). We restricted the search to randomised
controlled trials in humans, reported in English, and published
during 2000-12.
Acronym identification
In the included studies we looked for the meaning of the
acronym in several sources in the order of title, abstract, full
text, and trial registration (if any). AP, MBH, and MRH
performed the initial search, further aided by CG, TBS, KSL,
PMM, LHVM, and DD in identifying acronyms. In case of any
uncertainty by the single reviewer, the information was double
checked by both MBH and MRH.
Acronym evaluation
The evaluation consisted of both positive (BEAUTY, Boosting
Elegant Acronyms Using a Tally Yardstick) and negative
(CHEATING, obsCure and awkHward usE of lettArs Trying
to spell somethING) criteria (box). We used a two step Delphi
method to agree on these criteria.11 The final score assigned to
each acronym was obtained by adding the BEAUTY and
CHEATING score.
To assess the inter-rater reliability of the combined score we
rescored 100 randomly selected acronyms.12 13 We also
subjectively evaluated whether the acronym could be considered
as “cool” (for example, had a witty cultural reference) or
pretentious, or the quality of the language of the full title had
suffered in a strained attempt to make the acronym fit better.
We did not include these subjective measures in the overall
score.
Finally, we identified a list of honourable and dishonourable
mentions that for some reason did not obtain a particularly high
or low score but still deserve to be highlighted.
Analysis
We reported the proportion of acronym use and the median
quality score of acronyms over time.We reported the 25 highest
and lowest scoring acronyms and the honourable and
dishonourable mentions selected by the reviewers. One way
analysis of variance was used to compare overall scores between
different medical specialties. To determine if the prevalence of
acronyms in cardiology was higher than that in the other
specialties, we performed a χ2 test. The change in quality of
acronyms over time was assessed using a Spearman’s rank
correlation. For the top and bottom 25 acronyms, we identified
the impact factor of the publishing journal in the year of
publication, total number of citations, and average yearly
citations.14 We compared the 25 highest and lowest scoring
acronyms using an unpaired Student’s t test after log
transformation.
Results
A total of 14 965 publications were identified, most of which
were within the disciplines of cardiology (n=5063) and
endocrinology (n=4994). Overall, 18.3% (n=2737) of the
publications contained a total of 1149 unique acronyms (table
1⇓). The prevalence proportion of acronyms increased over time
for all specialties, except for cardiology (P<0.01, fig 1⇓).
Excluding 197 acronyms where we could not identify the full
meaning, 952 acronyms underwent further evaluation. The
median quality score was 6.5, with scores ranging from −18 to
22 (interquartile range 3.0-10.5). One way analysis of variance
showed that the correlation between score andmedical specialty
was not statistically significant. Tables 2⇓ and 3⇓ present the
25 highest and lowest scoring acronyms. Over the study period
the acronym quality score declined significantly (P<0.01, fig
2⇓). The honourable and dishonourable mentions are listed in
tables 4⇓ and 5⇓.
The intraclass correlation coefficient of the combined score was
0.91 (95% confidence interval 0.86 to 0.94), indicating almost
perfect agreement.
Overall, 4.4% (n=42) of the acronyms contained poor language
in an attempt to improve on the acronym, 11.5% (n=109) were
designated as “cool,” with cardiology and pulmonary medicine
in the lead with 12.9% and 10.7%, respectively, and psychiatry,
rheumatology, and endocrinology following with 2.8%, 5.8%
and 9.8%, respectively. Although 12.8% (n=122) of all acronyms
were classified as excessively pretentious, this proportion varied
between specialties: from psychiatry (19.4%), rheumatology
(15.4%), pulmonary medicine (14.3%), endocrinology (13.9%),
to, lastly, cardiology (11.8%).
The top 25 acronyms were published in journals with a median
impact factor of 10.2 (interquartile range 6.8-28.9), whereas the
bottom 25 had a median impact factor of 6.1 (3.3-11.4). This
difference failed to reach significance (P=0.05). The top 25
acronyms had more total citations (median 69 v 29, P=0.02),
whereas citations per year did not differ significantly (median
14 v 7, P=0.09).
Discussion
This quantitative and qualitative systematic study showed an
increasing use of acronyms in the manuscript titles of four major
medical specialties coinciding with a noticeable decline in the
quality of the acronyms over time.
Cardiologists’ obsession with acronyms is well documented
and has been the subject of in-depth analysis.6 8 15-18 Although
the “10 commandments of acronymology” was suggested in
2003,6 these were never formally adopted by any cardiological
society. No biologically plausible reason explains the apparent
obsession with acronyms in cardiology. It may be hypothesised
that fierce academic competition spurred the origin of such use,
and that new researchers have been subject to peer pressure and
assigned acronyms at all cost to avoid academic marginalisation
and ridicule. Another hypothesis is a reversal of the process:
cardiologists may first concoct a clever acronym and then design
a trial to fit that acronym.
Between the top 25 and bottom 25 acronyms, studies with good
acronyms had more citations than studies with poor acronyms.
For manuscript titles with good acronyms we observed a
non-significant trend towards publication in journals with a
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Criteria used for evaluation of acronyms
Positive criteria
BEAUTY—Boosting Elegant Acronyms Using a Tally Yardstick
Scores calculated:
1.5 points for each letter of acronym correctly used—that is, letters in the acronym that corresponded to the first letter in a word of the
title
5 points if acronym was a real word
2 points if acronym related to the specialty of study
Negative criteria
CHEATING—obsCure and awkHward usE of lettArs Trying to spell somethING
Scores calculated:
−2 points for each letter incorrectly used—that is, not the first in a word
−1 point for each letter that was almost correctly used—that is, followed a correctly used letter
−1 point for each word in the full title not accounted for in the acronym (not counting prepositions and adverbs)
−2 points for each letter in the acronym that could not be attributed to a word in the full title
higher impact factor. Bibliometric assessment of academic
production is closely associated with successful funding,19 20 as
well as personal satisfaction, pride, and peer prestige of
researchers.21-23 In line with our findings, a study found that
using an acronym was associated with a twofold increase in
annual citation rate.24 Furthermore, the length of a manuscript’s
title has been identified as an independent predictor of citation
rate.25 In that study, however, the authors failed to account for
acronymisation in their regression model. This possibly
represents a strong confounder, and we are confident that
adjusting for acronym use would eliminate the apparent signal
from title length.25 A causal relation cannot be inferred from
our results though, and the issue of reverse causality remains a
concern. We cannot exclude that well chosen and aesthetically
satisfying acronyms increase the impact factor of the journals
publishing them. However, we find it reassuring that acronyms
that are technically correct and aesthetically satisfying are
seemingly appropriately rewarded.
The Tolstoy manoeuvre
We observed several examples of what we designate the Tolstoy
manoeuvre: if the title appears to quote extensive passages from
War and Peace (>1400 pages), authors can fit any desired
acronym by cherry picking letters. A striking example is
ADJUST (Abatacept study to Determine the effectiveness in
preventing the development of rheumatoid arthritis in patients
with Undifferentiated inflammatory arthritis and to evaluate
Safety and Tolerability, table 3). Incidentally, this represents a
failed Tolstoy manoeuvre, as the “J” is not accounted for.
The good
Good acronyms are thoughtful, well designed, orthographically
correct, and aesthetically satisfying. Acronyms such as
CHARISMA, PREDICTIVE, and CAPTIVATE (table 3) are
excellent examples and all likely to serve the purpose of the
acronymisation to a meaningful extent. For pure inventiveness
and imagination, some very good acronyms were included on
the honourable mentions list, such as HI-5, DESSERT, and
RATPAC (table 4).
The bad
The RATIONAL, RECOVER, and EXAMINE (table 3)
acronymsmay at first glance appear quite reasonable. On further
examination, however, these acronyms reveal themselves to be
poorly constructed. Consider the completely wonderful
RATIONAL acronym, derived from “aspiRin stAtins or boTh
for the reductIon of thrOmbin geNeration in diAbetic peopLe.”
Orthographically, a worse acronym than this is literally
impossible to construct. Although the acronym signifies that
the study presents rational, clinically important data, as in
“rational pharmacotherapy” or “rational allocation of resources,”
such connotations seem disproportionate to the findings of the
study.26
The ugly
We identified several acronyms that were seemingly randomly
put together at the authors’ discretion and did not remotely
resemble a recognisable word or phrase. Prominent examples
include POLMIDES, ARMYDA-5, andMETGO (table 3). The
dishonourable mentions list includes abominations such as
SU.FOL.OM3 and P-No SOS (table 5), leaving acronymologists
around the world wondering why the authors bothered in the
first place.
We conclude that the prevalence of acronyms in reports on
clinical trials is increasing at the expense of their semantic and
aesthetic quality. Given the academic importance of acronyms,
we are surprised by the lack of effort dedicated to their
construction. The growth of acronym use, especially those of
poor quality, should be resisted.27 We believe that strict
governance of current guidelines by journal editors will result
in an aesthetic improvement and better use of acronyms.
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What is already known on this topic
The use of acronyms by medical researchers to brand their studies in the minds of clinicians and fellow researchers is subject to
controversy
The use of acronyms may be associated with a higher annual citation rate
What this study adds
The proportion of trials within major disease entities in rheumatology, endocrinology, pulmonary medicine, and psychiatry that uses
acronyms is increasing
The technical and aesthetic quality of acronyms is decreasing
Data sharing: Statistical code and datasets are available from the
corresponding author at apottegaard@health.sdu.dk.
Transparency: The corresponding author (AP) affirms that themanuscript
is an honest, accurate, and transparent account of the study being
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that any discrepancies are disclosed.
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Tables
Table 1| Basic search algorithm and results
Total No of acronymsNo (%) with acronym in titleNo of studiesMeSH termSpecialty
8041912 (37.8)5063Myocardial infarctionCardiology
299618 (12.4)4994Diabetes mellitus, type 2Endocrinology
69114 (8.1)1404Arthritis, rheumatoidRheumatology
5086 (5.1)1691Pulmonary disease, chronic obstructivePulmonary medicine
49150 (6.6)2284Depressive disorder, majorPsychiatry
11492737 (18.3)14 965Total*
*Differs from sum as studies might be related to more than one keyword.
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Table 2| 25 best acronyms according to composite BEAUTY and CHEATING criteria (see box for details of scoring)
Citations
/year†
No of
citations†Impact factor
Publication
yearSpecialtyFull name*AcronymTotal score
4.72831.72008ENPredictable Results and Experience in Diabetes through
Intensification and Control to Target: An International
Variability Evaluation
PREDICTIVE22.0
53.637531.72008ENPioglitazone Effect on Regression of Intravascular
Sonographic Coronary Obstruction Prospective Evaluation
PERISCOPE20.5
14.74430.02012CAImmediateMyocardial Metabolic Enhancement During Initial
Assessment and Treatment in Emergency care
IMMEDIATE19.5
6.0364.42009CAProspective Randomized Evaluation of Celecoxib Integrated
Safety versus Ibuprofen Or Naproxen
PRECISION18.5
2.5106.82011CABarrier approach to restenosis: restrict intima to curtail
adverse events
BARRICADE18.0
27.427423.42005PUBronchitis Randomized on NAC Cost-Utility StudyBRONCUS17.5
10.06028.92009CACarotid Atherosclerosis Progression Trial Investigating
Vascular ACAT Inhibition Treatment Effects
CAPTIVATE17.5
3.14610.92000CAPlatelet Receptor Inhibition in Ischemic Syndrome
Management in Patients Limited by Unstable Signs and
Symptoms
PRISM-PLUS17.5
51.081628.91999CADutch Echocardiographic Cardiac Risk Evaluation Applying
Stress Echocardiography
DECREASE17.0
11.51263.72004CAClopidogrel for High Atherothrombotic Risk and Ischemic
Stabilization, Management, and Avoidance
CHARISMA17.0
61.680129.12002CAControlled Abciximab and Device Investigation to Lower
Late Angioplasty Complications
CADILLAC17.0
3.34910.22000CAIncomplete Infarction Trial of European Research
Collaborators Evaluating Prognosis post-Thrombolysis
INTERCEPT17.0
30.92168.92008CAMagnetic Resonance Imaging for Myocardial Perfusion
Assessment in Coronary Artery Disease Trial
MR-IMPACT17.0
12.07230.82009PUPhospholipase Levels and Serological Markers of
Atherosclerosis
PLASMA16.0
7.21083.82000CAIntravenous NPA for the treatment of infarcting myocardium
early
InTIME16.0
2.392.12011PSImproving Mood with Psychoanalytic and Cognitive
Therapies
IMPACT16.0
--10.22000CAMicroalbuminuria Cardiovascular Renal Outcomes - Heart
Outcomes Prevention Evaluation
MICRO-HOPE16.0
1.022.52013PSBlacks Receiving Interventions for Depression and Gaining
Empowerment
BRIDGE16.0
3.3138.12011ENActive Prevention in High-Risk Individuals of Diabetes Type
2 in and Around Eindhoven
APHRODITE16.0
14.521710.92000CACan Routine Ultrasound Influence Stent ExpansionCRUISE16.0
54.85487.32005CAStudy of the Effects of Nebivolol Intervention on Outcomes
and Rehospitalisation in Seniors with Heart Failure
SENIORS15.5
1.3192.42000CACollaborative Angiographic Patency Trial Of Recombinant
Staphylokinase
CAPTORS15.5
22.615812.82008ENDiabetes Education and Self Management for Ongoing and
Newly Diagnosed type 2 Diabetes
DESMOND15.5
60.5108927.81997CAEfficacy and Safety of Subcutaneous Enoxaparin in
Non-Q-Wave Coronary Events
ESSENCE15.5
11.0667.72009ENComputerization of Medical Practices for the Enhancement
of Therapeutic Effectiveness
COMPETE15.5
CA=cardiology; EN=endocrinology; PU=pulmonary medicine; PS=psychiatry.
*Capitalisation is identical to that done by authors of single study.
†Source: Web of Knowledge.14
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Table 3| 25 worst acronyms according to composite BEAUTY and CHEATING criteria (see box for details of scoring)
Citations/year†
No of
citations†
Impact
factor
Publication
yearSpecialtyFull name*AcronymTotal score
5.7577.42005RHA 48-week, randomized, double-blind, double-observer,
placebo-controlled multicenter trial of combination
METhotrexate and intramuscular GOld therapy in
rheumatoid arthritis: results of the METGO study
METGO−18.0
17.06838.32011CAPrevention of cerebrovascular and cardiovascular Events
of ischaemic origin with teRutroban in patients with a history
oF ischaemic strOke or tRansient ischaeMic attack
PERFORM−18.0
12.5506.82011CATrial to assess the use of the CYPHer sirolimus-eluting
coronary stent in acute myocardial infarction treated with
BallOON angioplasty
TYPHOON−16.5
1.8112.72009CAinhibitory effect of valsartan against progression of lefT
VENTricUlaR dysfunction aftEr myocardial infarction
T-VENTURE−14.5
0.520.52011CAProspective randomised pilOt study evaLuating the safety
and efficacy of hybrid revascularisation in MultI-vessel
coronary artery DisEaSe
POLMIDES−13.5
50.735528.42008CAmorBidity-mortality EvAlUaTion of the If inhibitor ivabradine
in patients with coronary disease and left ventricULar
dysfunction
BEAUTIFUL−13.0
20.88314.22011CAInfluence of CILostazol-based triple antiplatelet therapy ON
Ischemic Complication after drug-eluting stenT implantation
CILON-T−12.0
2.1157.42008CAAssessment of the Medtronic AVE Interceptor Saphenous
Vein Graft Filter System
AMEthyst−12.0
0.832.32011CAEfficacy and safety of a double-coated paclitaxel-eluting
coronary stent
EUCATAX−11.0
2.063.72012ENaspiRin stAtins or boTh for the reductIon of thrOmbin
geNeration in diAbetic peopLe
RATIONAL−11.0
5.22614.32010CAAntiplatelet therapy for Reduction of MYocardial Damage
during Angioplasty
ARMYDA-5
PRELOAD
−10.5
2.374.52012CAEffect of METOprolol in CARDioproteCtioN during an acute
myocardial InfarCtion
METOCARD-CNIC−10.5
37.337344.02005CASIRolimus-eluting stent compared with pacliTAXel-eluting
stent for coronary revascularization
SIRTAX−10.5
11.0336.62012CAFacilitation through Aggrastat By drOpping or shortening
Infusion Line in patients with ST-segment elevation
myocardial infarction compared to or on top of PRasugrel
given at loading dOse
FABOLUS PRO−9.0
32.71969.82009CAMyocardial Regeneration by Intracoronary Infusion of
Selected Population of Stem Cells in Acute Myocardial
Infarction
REGENT−8.5
2.6292.92004ENORLIstat and CArdiovascular risk profile in patients with
metabolic syndrome and type 2 DIAbetes
ORLICARDIA−8.5
7.76911.42006CAStenting Coronary Arteries in Non-Stress/Benestent DiseaseSCANDSTENT−8.0
1.344.52012CAREstoration of COronary flow in patients with no-reflow
after primary coronary interVEntion of acute myocaRdial
infarction
RECOVER−8.0
1.9213.12004CACarbofilm-coated stent versus a pure high-grade stainless
steel stent
Carbostent−8.0
7.3956.12002CAValue of First Day Angiography/Angioplasty In Evolving
Non-ST Segment Elevation Myocardial Infarction: An Open
Multicenter Randomized Trial
VINO−7.0
0.743.32009CAThe effects of METhotrexate therapy on the physical
capacity of patients with ISchemic heart failure
METIS−7.0
8.4593.92008CAStent deployment Techniques on cLinicaL outcomes of
patients treated with the cypheRstent
STLLR−7.0
2.063.32012CAComparison of Biolimus Eluted From an Erodible Stent
Coating With Bare Metal Stents
COMFORTABLE−6.5
23.814312.52009CAImpact of Thrombectomy with EXPort Catheter in
Infarct-Related Artery during Primary Percutaneous
Coronary Intervention
EXPIRA−6.5
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Table 3 (continued)
Citations/year†
No of
citations†
Impact
factor
Publication
yearSpecialtyFull name*AcronymTotal score
6.5264.72011CAEXamination of cArdiovascular outcoMes with alogliptIN
versus standard of carE in patients with type 2 diabetes
mellitus and acute coronary syndrome
EXAMINE−6.5
CA=cardiology; EN=endocrinology; RH=rheumatology.
*Capitalisation is identical to that done by authors of single study.
†Source: Web of Knowledge.14
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Table 4| Honourable mentions
SpecialtyFull name*Acronym
CACangrelor versus standard tHerapy to Achieve optimal Management of Platelet InhibitiONCHAMPION
CAOngoing Telmisartan Alone and in Combination With Ramipril Global End Point TrialONTARGET
CAClinical Evaluation of the Xience-V stent in Acute Myocardial INfArcTIONEXAMINATION
CARandomised Assessment of Treatment using Panel Assay of Cardiac markersRATPAC
CAAldosterone Lethal effects Blocked in Acute myocardial infarction Treated with or without Reperfusion to improve
Outcome and Survival at Six months follow-up
ALBATROSS
CAEvaluation of Nitrous oxide In the Gas Mixture for AnesthesiaENIGMA
CAPatient Related OuTcomes with Endeavor versus Cypher stenting TrialPROTECT
CAAggrastat to ZocorA to Z
CADebulking Of CTO with Rotational or directional atherectomy before StentingDOCTORS
CADose confIrmation Study assessing anti-Platelet Effects of AZD6140 vs. clopidogRel in non-ST-segment Elevation
myocardial infarction
DISPERSE
CAAbciximab Before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long-term
Follow-up
ADMIRAL
CADie Deutsche Diabetes Dialyse Studie4D
CAVerapamil Slow-Release for Prevention of Cardiovascular Events After AngioplastyVESPA
CAAzimilide Postinfarct Survival EvaluationALIVE
CALosartan Intervention For Endpoint reduction in hypertensionLIFE
CAOmapatrilat in Persons with Enhanced Risk of Atherosclerotic eventsOPERA
CAHirulog Early Reperfusion OcclusionHERO
CAMonitoring and Actualization of Noetic TrainingMANTRA
CAHyperglycemia: Intensive Insulin Infusion in InfarctionHI-5
CAChest pain evaluation in the emergency roomCHEER
ENInvestigation of Lipid Level Management to Understand its Impact in Atherosclerotic EventsILLUMINATE
ENStudy Evaluating Rimonabant Efficacy in Drug-Naive Diabetic PatientsSERENADE
ENCardiovascular risk education and social supportCaRESS
ENDiabetes Drug Eluting Sirolimus Stent Experience in Restenosis TrialDESSERT
ENStudy on Lifestyle intervention and Impaired glucose tolerance MaastrichtSLIM
ENPLavix Use for Treatment Of DiabetesPLUTO
RATreating to Twin TargetsT-4
CA=cardiology; EN=endocrinology.
*Capitalisation of letters is identical to that done by authors of single study.
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Table 5| Dishonourable mentions
SpecialtyFull name*Acronym
CALoSmapimod treatment on inflammation and InfarCtSizESOLSTICE
CAPost-Myocardial Infarction Free Rx Event and Economic EvaluationMI FREEE
CASUpplementation with FOLate, vitamins B-6 and B-12 and/or OMega-3 fatty acidsSU.FOL.OM3
CAPROlonging Dual-antiplatelet treatment after Grading stent-induced Intimal hyperplasia studyPRODIGY
CATreatment of De Novo Coronary Disease Using a Single Paclitaxel-Eluting StentTAXUS
CAAntibiotic Therapy in Acute Myocardial InfarctionANTIBIO
CASingle High-Dose Bolus Tirofiban and Sirolimus Eluting Stent Versus Abciximab and Bare Metal Stent In
Acute Myocardial Infarction
STRATEGY
CAPrimary angioplasty in acute myocardial infarction at hospitals with no surgery on-siteP-No SOS
ENVeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerYVICTORY
ENCaptopril Prevention ProjectCAPPP
PUMaintenance of Haemoglobin Excels IV Administration of C.E.R.A.MAXIMA
RAAbatacept study to Determine the effectiveness in preventing the development of rheumatoid arthritis in
patients with Undifferentiated inflammatory arthritis and to evaluate Safety and Tolerability
ADJUST
CA=cardiology; EN=endocrinology; RH=rheumatology; PU=pulmonary medicine.
*Capitalisation of letters is identical to that done by authors of single study.
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Figures
Fig 1 Prevalence proportion of acronyms over time
Fig 2 Median quality score for acronyms by year
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